RE:RE:Locking in PROFITSRixpix, We have 5 patients all expressing insulin and trending towards the first patient. It is more than fair to compare to peers. If anything, peers cant be compared to Sernova because they are still preclinical and haven't even shown that their cells can be vascularized let alone expressing insulin or other blood-clotting proteins . Sgtx tradded in the last month at 2B canadian almost 10x our current valution.
Re hyperglycemia all glucose parameters have been improving including hyperglycemia. Further work on dosing will continue this improvement. The important thing right now is islet cells are vascularized strongly producing insulin and patients have no adverse effects. One patient with insulin independence is a major unexpected bonus at this stage.